The human immunodeficiency virus type 1 (HIV-1) Vpr protein is known to arrest the cell cycle in G 2 /M and induce apoptosis following arrest. The functions of Vpr relative to its location in the cell remain unresolved. We now demonstrate that the location and function of Vpr are dependent on the makeup of fusion proteins and that the functions of G 2 /M arrest and apoptosis are separable. Using green fluorescence protein mutants (EGFP or EYFP), we found that fusion at either the N-or C-terminus compromised the ability of Vpr to arrest cell cycling, relative to that of His-Vpr or wild-type protein. Additionally, utilizing the ability to specifically identify cells expressing the fusion proteins, we confirm that Vpr can induce apoptosis, but appears to be independent of cell-cycle arrest in G 2 /M. Both N-and C-terminal Vpr/EYFP fusion proteins induced apoptosis but caused minimal G 2 /M arrest. These studies with Vpr fusion proteins indicate that the functions of Vpr leading to G 2 /M arrest and apoptosis are separable and that fusion of Vpr to EGFP or EYFP affected the localization of the protein. Our findings suggest that nuclear membrane localization and nuclear import and export are strongly governed by modification of the N-terminus of Vpr.
Introduction
Human immunodeficiency virus type 1 (HIV-1) encodes a series of proteins from the structural and regulatory genes gag, env, pol, tat, and rev, to the accessory genes vpr, vif, vpu, and nef. The accessory proteins are not essential for HIV-1 replication in vitro; however, they do play an important role in modulating the virus life cycle in vivo (Cullen and Greene, 1990; Trono, 1995) . The accessory gene vpr encodes a 96 amino acid, 15-kDa protein. Vpr is packaged into viral particles (Yuan et al., 1990) through an interaction with the p6 region of the Pr55 Gag precursor protein (Kondo and Gottlinger, 1996; Lavallee et al., 1994; Lu et al., 1995; Mahalingam et al., 1997; Paxton et al., 1993; Sato et al., 1996) . Vpr is reported to be dispensable for virus replication in human T cell lines and primary CD4 ϩ lymphocytes, but is important for infection of monocytes and macrophages (Akari et al., 1992; Balliet et al., 1994; Cohen et al., 1990; Connor et al., 1995; Dedera et al., 1989) . The role of Vpr in translocation of the viral preintegration complex (PIC) into the nucleus of the newly infected cell (Heinzinger et al., 1994) and transactivation of the HIV-1 LTR is important in infection of such nondividing cells (Agostini et al., 1996; Vanitharani et al., 2001) .
In several studies, Vpr has been shown to accumulate in the nuclei of infected and transfected cells (Di Marzio et al., 1995; Lu et al., 1993; Mahalingam et al., 1995; Zhao et al., 1994) . There have been two major regions of Vpr identified to be involved in nuclear localization (Jenkins et al., 1998) . The first is the N-terminal ␣-helix encompassing residues 17 to 34 (Mahalingam et al., 1995; Yao et al., 1995) . The second region comprises residues 53 to 78, that can also form an ␣-helix (Schuler et al., 1999) . Expression of Vpr causes an arrest of cell cycling and the subsequent accumulation of cells in the G 2 /M phase of the cell cycle (Jowett et al., 1995; Rogel et al., 1995) . Vpr is conserved among the primate lentiviruses (Planelles et al., 1996) and has been shown to arrest cell cycling in both mammalian and yeast cells (Zhang et al., 1997; Zhao et al., 1996) . Conservation of both Vpr and its manipulation of the host cell alludes to the potential key role Vpr plays in the life cycle of HIV-1.
Vpr has been implicated in both the induction (Jacotot et al., 2000; Shostak et al., 1999; Stewart et al., 1997 Stewart et al., , 1999 Stewart et al., , 2000 and the prevention (Conti et al., 1998; Fukumori et al., 1998) of apoptosis. In some studies, Vpr-mediated apoptosis has been shown to be dependent on the induction of G 2 /M arrest (Stewart et al., 1997; Watanabe et al., 2000; Yao et al., 1998) . The family of caspases comprises the effector arm of apoptosis, and Vpr has been shown to induce the activation of a number of these proteins (Patel et al., 2000; Stewart et al., 2000) . The function of Vpr, in regard to apoptosis, may be either induction or inhibition dependent upon the level of expression, subcellular location, and possibly other factors present in the cell.
Understanding the localization of Vpr relative to its functions may provide insight into potential cellular partners for the execution of these functions. Indeed, HIV-1 Vpr has been studied as a GFP C-terminal fusion protein in terms of localization and/or function with different outcomes noted (Sherman et al., 2001; Zhu et al., 2001) . To further define the localization and function of HIV-1 Vpr, the enhanced green or yellow fluorescent proteins (EGFP or EYFP, respectively) derivatives of GFP from the jelly fish Aequorea victoria were chosen as both N-and C-terminal fusion partners. A large number of studies have demonstrated the innocuous behavior of GFP as a fusion partner (Doyle and Botstein, 1996; Stearns, 1995; Straight et al., 1997; Westphal et al., 1997) . However, any concerns relating to the functional integrity of a GFP-fusion protein are readily addressed by functional analysis of both N-and C-terminally tagged constructs (Kaech et al., 1996) . EGFP has been used extensively in mammalian expression systems as a marker of transfection efficiency and to determine subcellular localization of fused proteins (Chalfie et al., 1994; Wang and Hazelrigg, 1994) . The subcellular localization of proteins fused to EGFP or EYFP can also be studied without distribution variation due to fixation procedures (Brock et al., 1999) .
Hence, to assess the subcellular localization and function of HIV-1 Vpr, we constructed both N-and C-terminal EGFP or EYFP fusion proteins with Vpr and also used Vpr and/or a His-tagged protein as controls. Subcellular localizations were determined in three cell lines by confocal microscopy, and the function of the proteins was assessed by examining their effects on cell cycling and apoptosis. We show that both Vpr fusion proteins were unable to significantly arrest cells in G 2 /M compared with Vpr or His-Vpr, whereas all four proteins caused apoptosis in HeLa cells. Additionally, fusion of EGFP or EYFP to the N-or C-terminus of Vpr had a dramatic effect on cellular localization.
Results

Level of transfection efficiency and expression of EGFP and Vpr fusion proteins by flow cytometry
The mammalian cell lines 293T, 293, and HeLa were transiently transfected with pEGFP, pEGFP-Vpr, or pVpr-EGFP. Analysis by flow cytometry was used to determine the percentage of cells transfected and level of protein expression ( Fig. 1) . The transfection efficiency of the various plasmids ranged from 45 to 99% of the gated populations in the three cell lines. A bimodal distribution of fluorescence was evident for EGFP expression alone in all three cell types. This distribution corresponded to populations of high and low relative fluorescence. The bimodal distribution of relative fluorescence was not as obvious for both Vpr fusion proteins in all cell types. High transfection efficiencies were consistently achieved, suggesting that most of the Fig. 1. Transient transfection of pEGFP, 293, or HeLa cells as measured by FACS analysis. Cells were assessed at 48 h posttransfection. Each sample transfected with EGFP or an EGFP fusion protein is shown in gray relative to the mock-transfected cells (vector alone), shown in black. Gates marked were set according to cells transfected with pEN-1. population was expressing the Vpr fusion proteins to significant levels (Fig. 1) . A point to note is that the fluorescence intensity was consistently lower for the Vpr fusion proteins than EGFP alone, particularly for HeLa cells. This is important in terms of the possible effects of Vpr on the level of expression and for coincident analyses of Vprpositive populations.
Confirmation of protein expression by immunoblotting
To verify the expression of EGFP, EGFP-Vpr, Vpr-EGFP, and His-Vpr, transiently transfected cells were lysed and analyzed by immunoblotting ( Fig. 2) . Preliminary timecourse experiments in 293T cells indicated 24 to 48 h posttransfection was optimal for peak expression of these proteins ( Fig. 2A) . A polyclonal antibody directed against GFP and/or Vpr detected bands corresponding to EGFP-Vpr or Vpr-EGFP ( Fig. 2A ) that were 42 to 43 kDa in size. EGFP-Vpr was consistently found to be marginally smaller in molecular weight than Vpr-EGFP. Sequence analysis of the two plasmids indicated that the expressed fusion proteins should be identical in size (data not shown). The size difference and detection was consistent in all three cell types tested ( Figs. 2A, B , and C). The EGFP-Vpr and Vpr-EGFP proteins were also detected with a polyclonal antibody directed against amino acids 2 to 21 of Vpr (Figs. 2B and C, . This antibody also detected the 15-kDa His-tagged Vpr (Fig. 2D ), albeit weakly. On occasion we also observed a breakdown product of EGFP-Vpr with the anti-Vpr; this represented Ͻ10% of the total protein. Expression levels of the fusion proteins were consistently greater than His-tagged Vpr despite equivalent DNA input in the transfections.
Localization of Vpr fusion proteins in 293T, 293, and HeLa cells
The localization of EGFP, EGFP-Vpr, and Vpr-EGFP proteins in the three cell lines was determined by confocal microscopy (Fig. 3A ). The EGFP protein was distributed throughout the cell in all cell lines, although there was some exclusion from nucleoli and cytoplasmic vacuoles. The localization of EGFP-Vpr was principally (Ͼ90%) in the nuclei of transfected HeLa, 293, and 293T cells. Clear exclusion from the nucleoli and some accumulation at the nuclear membrane was also evident ( Fig. 3A , g-i). Strikingly, expression of Vpr-EGFP resulted in a very different pattern, with the fusion protein predominantly (Ͼ90%) localized to the nuclear membrane ( Fig. 3A, d-f ). There was also some protein observed in the nuclei of cells expressing Vpr-EGFP, albeit less compared with EGFP-Vpr, and notably there were intense foci of fluorescence in the cytoplasm of transfected cells (approximately 40%). Localization of each of the fusion proteins in the three different cell types was similar. The expression levels of the proteins of . At 72 h posttransfection, the DNA of the cells was stained using Hoechst 33342. The cells were viewed and photographed with a Zeiss fluorescent microscope using a ϫ40 objective. The Hoechst staining is shown in blue (a and c), while the green fluorescence of Vpr-EGFP is shown in green (b). Please note the EGFP is as viewed by fluorescence microscopy and not by confocal microscopy, hence viewing the whole cell rather than a cross-section as shown in A. The arrows denote cells with fragmented DNA, indicative of apoptotic cells. At 48 h posttransfection, cells were fixed with 3.5% paraformaldehyde, permeabilized with methanol:acetone (1:1), followed by staining for immunofluorescence with anti-Vpr antibodies (a and b), fixed with 3.5% paraformaldehyde (c and e), or fixed with 3.5% paraformaldehyde followed by permeabilization with methanol:acetone (1:1) (d and f). Typical representations of the subcellular localization were recorded using confocal microscopy using a ϫ60 objective. interest were greater by both fluorescence and immunoblotting in 293 and 293T cells (Figs. 2 and 3A) . Nuclear membrane localization was confirmed by coincidental staining with nucleoporin p62 in the three cell types (data not shown). Permeabilizing the cells for detection of p62 protein altered the distribution of the EGFP fusion proteins in that they appeared more diffuse.
Localization of His-Vpr in 293T, 293, and HeLa cells
The structure of EGFP is cylindrical and very compact. However, it is still a relatively large fusion partner of 28 kDa. The pHis-Vpr NL expression plasmid provided a source of HIV-1 Vpr with a small, 6 amino acid histidine tag. Localization of His-tagged Vpr protein in 293T, 293, and HeLa cells was also examined by confocal microscopy (Fig.  4A ). Antibodies directed against Vpr (amino acids 2 to 21) or the His-tag specifically detected the expressed protein.
The protein was found to localize predominantly in the region of the nuclear membrane; however, fluorescence was diffuse in comparison to expression of the fusion proteins. The pattern of cellular expression was the same using both anti-Vpr and anti-His antibodies. Permeabilization of the cells resulted in a more diffuse fluorescence as demonstrated by a direct comparison to Vpr-EGFP using the same conditions. Distribution was also altered with more protein observed in the cytoplasm (Fig. 4B ). The fluorescence pattern was much more diffuse, very similar to that observed in cells transfected with His-Vpr NL (Fig. 4B, a and b ). Strikingly, cells expressing EGFP-Vpr that were fixed exhibited almost complete nuclear localization compared to permeabilized cells which showed additional cytoplasmic staining (Fig. 4B , e and f). Cellular morphology was also not as well defined in permeabilized cells. We also did coincident Hoechst staining on occasion, further confirming predominant nuclear localization and also fragmented nuclei, indicative of apoptosis ( Fig. 3B) .
Kinetics of the distribution of Vpr fusion proteins
Using this defined in situ localization technique, we next followed the kinetics of localization of the Vpr fusion proteins. Additionally, we also compared EYFP fusion proteins with those of EGFP for subsequent coincident apoptosis analyses of transfected cells. First, we found that the pattern of fluorescence was very similar among equivalent EGFP or EYFP Vpr fusion constructs and in the three cell types over the 72 h tested (data not shown). Representative results for Vpr-EYFP and EYFP-Vpr in transfected HeLa cells at 24, 48, and 72 h posttransfection are detailed in Fig. 5 . Kinetic studies revealed a change in the distribution over time for both Vpr fusion proteins. After nuclear membrane localization of Vpr-EYFP by 48 h, there was subsequently an increased amount of expressed protein accumulating in cytoplasmic foci, predominantly in perinuclear regions (compare Figs. 5a, b, and c). This predominant perinuclear lo-calization increased from Ͻ20% at 24 h to Ͼ50% at 72 h posttransfection. Cytoplasmic foci, although present earlier, were not necessarily perinuclear nor as prominent.
For EYFP-Vpr, nuclear localization was observed but there were also focal areas of fluorescence in both the nucleus and the cytoplasm (Figs. 5d and e). Similar to the C-terminal fusion proteins, these fusion proteins also increasingly aggregated in the perinuclear region with faint nuclear membrane localization by 72 h posttransfection (Fig. 5f ).
Effect of Vpr fusion proteins and His-Vpr on cell cycling
Extensive studies have shown that HIV-1 Vpr is able to induce G 2 /M arrest in multiple cell types (Goh et al., 1998; Jowett et al., 1995; Poon et al., 1998; Rogel et al., 1995) . We assessed the functional integrity of the Vpr fusion proteins in comparison to constructs expressing HIV-1 Vpr or His-Vpr. Experiments were performed in the three cell types used in the localization studies. While we were unable to reproducibly demonstrate significant G 2 /M arrest in either 293 or 293T cells with the control Vpr plasmids (Vpr or His-Vpr; data not shown), we were clearly able to see G 2 /M arrest in HeLa cells by these proteins when compared to controls (Fig. 6 ).
HeLa cells transiently transfected with pEGFP, pEYFP, pEGFP-Vpr, pVpr-EGFP, pEYFP-Vpr, pVpr-EYFP, pcDNA3.1 Vpr, and His-Vpr were stained with propidium iodide and the DNA content of the cells was analyzed by flow cytometry (Fig. 6 ). The percentage of gated cells in G 0 /G 1 and G 2 /M were measured and the ratios of G 2 /M: G 0 /G 1 were calculated. Except for the mock-transfected samples, gates were set to include only those cells that were positive for EGFP or EYFP expression. Cells expressing Vpr or His-Vpr resulted in a significant accumulation of cells in G 2 /M, with a G 2 /M:G 0 /G 1 ratio of Ͼ1 by 72 h posttransfection (Fig. 6 ). In comparison to mock-transfected cells, those expressing EGFP (data not shown) or EYFP alone showed similar values to the negative control. This was also the case for pcDNA3.1VprR73S, a mutant attenuated in its ability to arrest cells in G 2 /M (Sawaya et al., 2000) . In contrast to cells accumulating in G 2 /M for Vpr or His-Vpr, the fusion constructs all showed the reverse. HeLa cells appeared transiently arrested in G 2 /M early posttransfection (24 h), but this reduced over time to the extent that it was even less than the EYFP controls by 72 h posttransfection ( Fig. 6) . Results in 293 and 293T transfected cells were equivocal, but there appeared to be a similar effect albeit less pronounced (data not shown).
Vpr fusion proteins induce apoptosis in transfected HeLa cells
Propidium iodide staining of 293T, 293, and HeLa cells transfected with pEGFP, pVpr-EGFP, or pEGFP-Vpr and analyzed for DNA content 24 to 72 h posttransfection re-vealed there was an increase in the sub-G 0 population for those expressing Vpr-EGFP and EGFP-Vpr (data shown for 72 h posttransfection; Table 1 ). There was little change in the percentage of cells in the sub-G 0 population for 293T cells with the exception of those cells transfected with pEGFP-Vpr and pHis-Vpr (Table 1) . This and the cell-cycle arrest data prompted a more definitive study in HeLa cells.
As expression and location of Vpr EYFP and EGFP fusion proteins were shown to be very similar in all cell types tested, an apoptotic marker (Caspase 3) that was readily quantifiable with EYFP-transfected cells by FACS analysis was selected to assess coincident apoptosis. Results of PI or Hoechst staining demonstrated that 72 h was optimal for detection of cell death (data not shown). The selection of CaspACE FITC-VAD-FMK (CaspACE)-a relatively late marker of apoptosis-was based on previous studies (Muthumani et al., 2002; Stewart et al., 2000) which showed that apoptosis induced by HIV-1 Vpr required caspase activation. Transfected cells were analyzed for staining by CaspACE by flow cytometry, and the percentage of positively stained cells in the EYFP-positive popu-lation was used to measure apoptotic transfected cells (see Fig. 7A for representative flow cytometric cell distribution).
Analysis revealed that 0.9 and 14.9% of the mock-transfected and EYFP-transfected populations, respectively, were apoptotic (Fig. 7B ). CaspACE-positive cells expressing Vpr and His-Vpr comprised 28.8 and 24.5%, respectively, of the transfected population, while VprR73S demonstrated no ability over transfected controls to induce apoptosis, with 8.5% of cells apoptotic. In fact this value was even lower than that of EYFP-transfected cells. In contrast, 51.2 and 49.0% of Vpr-EYFP-and EYFP-Vprexpressing cells, respectively, were CaspACE positive, indicating significantly increased apoptosis in cells expressing either fusion protein. In comparison, the positive controls (cells treated with 2.5 and 5 g/ml of Actinomycin D) showed slightly higher levels of apoptosis, with 51.3 and 60.8% of cells, respectively, staining positive for CaspACE.
By this caspase 3 staining method, reduced levels of apoptosis were observed in 293 and 293T cells, when compared with HeLa cells (data not shown). The level of apoptosis in EYFP-transfected cells obscured any effect of these Vpr constructs in causing cell death and suggested that much of the induced apoptosis observed was due to transfection with DNA or the calcium phosphate transfection process itself.
In HeLa cells, Vpr and His-Vpr consistently demonstrated similar abilities to induce apoptosis, indicating that the histidine tag had no dramatic effect on this Vpr function. Vpr fusion proteins were also consistent in their abilities to induce markedly higher levels of apoptosis, with almost a 100% increase in the number of apoptotic cells compared with cells expressing Vpr or His-Vpr. This approximated the levels achieved by treatment of cells with the drug Actinomycin D. 
Discussion
The use of EGFP/EYFP as fusion partners at the N-or C-terminus defined Vpr localization in situ to the nucleus and nuclear membrane, respectively, and allowed coincident functional analyses. Fusion of Vpr to EGFP or EYFP at either the N-or the C-terminus affected its ability to arrest cells in G 2 /M. Apoptosis induced by both these proteins was Caspase 3 dependent and independent of coincident cellcycle arrest in G 2 /M.
Using N-and C-terminal GFP (EGFP and EYFP mutants) fusion proteins, we have convincingly shown the localization of HIV-1 Vpr to be at the nuclear membrane or in the nuclei of transiently transfected cells, depending upon the fusion construct. His-tagged Vpr expressed protein predominantly localized at the nuclear membrane with some nuclear localization, very similar to the N-terminal fusion proteins (Vpr-EGFP or Vpr-EYFP). The more diffuse pattern observed with the localization of His-Vpr may be accounted for by the necessity to permeabilize these cells prior to staining. Hence, subcellular localization of His-Vpr could not be visualized under the same physiological conditions as EGFP-Vpr/EYFP-Vpr and Vpr-EGFP/Vpr-EYFP. The localization pattern for each of the expressed proteins did not vary significantly between the three cell lines tested (293T, 293, and HeLa).
Despite Vpr-EGFP, Vpr-EYFP, and His-Vpr all predominantly localizing at the nuclear membrane, only His-Vpr resulted in sustained arrest of HeLa cells in G 2 /M. These results imply that fusion of EGFP to Vpr compromises its ability to cause sustained G 2 /M arrest despite a similar pattern of localization to that of His-Vpr. Interestingly, there was a transient G 2 /M arrest observed early after transfection with the Vpr fusion proteins. Such arrest was unaccompanied by apoptosis (data not shown) and may relate to the wider distribution of the protein throughout the cell early after transfection, as opposed to almost exclusive localization at the nuclear membrane by 48 h (Figs. 5a and d) . Vpr expressed alone also provided a control that resulted in similar G 2 /M arrest to that of His-Vpr. Despite higher levels of expressed protein for the Vpr fusion proteins as observed using an anti-Vpr antibody, the effect on cell cycling was not as marked. These results imply that fusion of EGFP or EYFP to Vpr compromises its ability to cause sustained G 2 /M arrest despite a similar pattern of localization to His-Vpr.
In contrast to a transient arrest in G 2 /M for Vpr-EGFP/ Vpr-EYFP and EGFP-Vpr/EYFP-Vpr, particularly in HeLa cells, the subsequent apoptosis induced was more dramatic than that observed for either His-Vpr or Vpr alone. Significantly, higher levels of cell death by apoptosis were induced by Vpr fusion proteins in HeLa cells than by the other proteins tested, including the Vpr positive control. The level of apoptosis may be related to differences in the relative levels of protein expression. The 293 and 293T cells showed some differences in the extent of apoptosis caused by the proteins expressed from the various Vpr constructs studied, but the results were not as marked. The lack of cell-cycle arrest and lower levels of apoptosis observed in 293 and 293T cells could have been due to the fact that these cells express the adenovirus E1A and E1B proteins. These may disrupt the function of Vpr by their actions on p53 and caspase activation (Hay and Kannourakis, 2002) .
In comparison, a mutant Vpr R73S, previously shown to be expressed at high levels throughout the cell, was compromised in both G 2 /M arrest and induction of apoptosis, indicating that mutation at position 73 is within a key functional domain of Vpr, supporting and extending previous studies showing ablation of cell-cycle arrest (Sawaya et al., 2000) . As this mutation is near the end of the C-terminal ␣-helix, it may be acting similarly to a H71R mutant previously described . Fusion resulted in a partial loss of Vpr function, whereas mutation resulted in complete loss of the two functions analyzed. Previous studies showed that Vpr R73S also had a transdominant negative effect on transcriptional activation of HIV-1 LTR (Sawaya et al., 2000) .
Several groups have reported Vpr-induced apoptosis (Jacotot et al., 2000; Shostak et al., 1999; Stewart et al., 1997 Stewart et al., , 1999 Stewart et al., , 2000 Yao et al., 1998) , and in some instances it has been linked to cell-cycle arrest (Stewart et al., 1997; Watanabe et al., 2000; Yao et al., 1998) . We have shown that expression of Vpr-EGFP/EYFP induced apoptosis in HeLa cells. This fusion protein localizes to the nuclear membrane and does not cause sustained cell-cycle arrest. Based on the apoptosis and cell-cycling results in HeLa cells, Vpr-induced cell-cycle arrest and apoptosis appear to be separable functions, as significant levels of apoptosis were observed coincident with relatively low levels of G 2 /M arrest. The lack of apoptosis seen at 24 h posttransfection, when G 2 /M arrest was apparent in cells transfected with the Vpr fusion plasmids, reinforces the independence of these two Vpr functions (data not shown). This view is supported by mutational studies by Chen et al. (1999) and Nishizawa et al. (2000) , in which Vpr mutants were able to induce either G 2 /M arrest or apoptosis, but not both. The extensive Caspase 3 dependent apoptosis occurring 72 h posttransfection coincided with late changes in the localization of each of the fusion proteins. The apparent perinuclear accumulation and nuclear blebbing may relate to the mechanism of Vpr-induced apoptosis. This has been shown recently as Caspase 9 dependent and mitochondrial dependent (Jacotot et al., 2000; Muthumani et al., 2002) . Preliminary studies utilizing a mitochondrial specific stain of viable cells did not indicate complete colocalization of Vpr fusion proteins and mitochondria (M.G. Waldhuber and D.A. McPhee, unpublished observations). The possible accumulation of Vpr fusion protein-laden debris in the perinuclear region over time and with cell division may also be a reason for the large intense areas observed late after transfection. Perhaps Vpr prevents the natural cycling of nuclear membrane associated protein(s).
The HIV-1 Vpr protein has two major regions important for nuclear localization. These can function independently, as demonstrated by the use of truncated Vpr constructs (Jenkins et al., 1998) . The first is an N-terminal ␣-helix, residues 17 to 34 (Mahalingam et al., 1995; Yao et al., 1995) , which forms a nonconventional nuclear localization signal (NLS) (Karni et al., 1998) . Vpr also harbors a second ␣-helix, residues 53 to 78 (Schuler et al., 1999) . Disruption of this latter domain has been shown to result in the accumulation of Vpr in the nuclear periphery . Additionally, the carboxy-terminus of Vpr (aa 73 to 96) contains a bipartite nuclear localization signal (Sherman et al., 2001; Zhu et al., 2001) . These studies with a GFP-pyruvate kinase (PK) chimera fused to Vpr (73-96) showed localization principally in the nucleus. Surprisingly, a full-length Vpr fusion (GFP-PK-Vpr) protein was almost exclusively observed in the cytoplasm. Addition of a nuclear export inhibitor (leptomycin B) revealed nuclear shuttling with predominant cytoplasmic localization. In contrast to cytoplasmic localization of GFP-PK-Vpr (fusion at the N-terminus of Vpr), a study with EGFP-Vpr (fusion protein at the N-terminus of Vpr with a flexible linker) showed nuclear localization. These results are quite similar to our results with EGFP-Vpr or EYFP-Vpr (fusion to the N-terminus of Vpr). Nuclear membrane localization of Vpr has been demonstrated in studies by Vodicka et al. (1998) , similar to the results shown here for His-Vpr and Vpr fused at the C-terminus. The presence of Vpr at the nuclear membrane is consistent with its role in translocation of the preintegration complex, which may involve association of Vpr with importin-␣ and the nucleoporins (Popov et al., 1998; Vodicka et al., 1998) , or other receptors (Jenkins et al., 1998) . The nuclear membrane localization of Vpr-EGFP was confirmed from our coincidental studies with His-Vpr and Vpr alone. Our EGFP-Vpr behaved similarly to Vpr-␤gal in other studies where predominant localization in the nucleus, excluding nucleoli, was observed (Jenkins et al., 1998) .
From our studies, it would appear that the localization of Vpr to the nuclear membrane, as clearly seen with Vpr-EGFP/EYFP and His-Vpr, is the result of the powerful NLS at the N-terminus of Vpr. Fusion to GFP at the N-or the C-terminus differentially affected localization and by inference probably nucleocytoplasmic shuttling (Sherman et al., 2001) . Fusion to the N-terminus saw efficient transport to the nucleus, whereas fusion to the C-terminus resulted in very efficient localization to the nuclear membrane, suggesting rapid uptake and egress from the nucleus resulting in the accumulation observed. The differences observed between the nuclear membrane localization of Vpr-EGFP/ EYFP and His-Vpr and the greater predominance of EGFP/ EYFP-Vpr in the nucleus can be explained by the effect of EGFP/EYFP on the localization of Vpr. Fusion of the protein to the N-terminus of Vpr appears to attenuate the function of this NLS. Construction of a C-terminal fusion protein was designed to avoid any interference with the N-terminal NLS of Vpr by EGFP/EYFP. Comparison with the N-terminal fusion protein illustrates how this can be affected and needs to be taken into account when designing fusion protein expression vectors. We chose to use EGFP/ EYFP fusion proteins because they are simple and effective markers for transfected cells, and their use as fusion proteins circumvents the need for staining with fluorophores or cotransfection with a marker of efficiency.
There have been various reports regarding any interaction between the subcellular localization of Vpr and its ability to arrest the cell cycle. Some studies have presented evidence that the two functions are related, stating that Vpr must be localized in the nucleus to induce arrest Zhou et al., 1998) . However, evidence has also been presented that Vpr-induced arrest and its subcellular localization are separate functions so that Vpr mutants that localize to the cytoplasm are still able to induce arrest (Mahalingam et al., 1997; Vodicka et al., 1998) . In this study, we have shown that His-Vpr is able to arrest the cell cycle and cause an accumulation of cells in G 2 /M when it is predominantly localized to the nuclear membrane and the nucleus of transfected cells. However, fusion of Vpr to EGFP/EYFP attenuates its cell-cycle arrest function, and this is irrespective of whether the construct is an N-or C-terminal fusion plasmid. It is possible that the introduction of a spacer arm between EGFP/EYFP and Vpr may alleviate the effect EGFP has on Vpr. Therefore, attention and care must be paid to the design and choice of fusion constructs and comparison of N-and C-terminal fusion proteins to ensure no compromise of function. This study has clearly demonstrated that localization to the nuclear membrane is not sufficient to cause G 2 /M arrest. Therefore, arrest and localization are separate functions of HIV-1 Vpr and additionally, induction of caspase-dependent apoptosis is another potentially independent outcome of the effect of Vpr on the host cell.
Materials and methods
Construction of plasmids
The HIV-1 vpr gene was amplified by PCR from the molecular clone pNL4-3. The forward 5Ј-G GAA ACT AAG CTT GCC ACC ATG GAA CAA GCC CCA GAA G and reverse 5Ј-GG GCT GGA TCC GCG GAT CTA CTG GCT CCA TTT C primers were designed to incorporate the restriction enzyme cut sites HindIII and BamHI, respectively (underlined). The Kozak consensus sequence is shown in bold. The 319-bp product was digested and cloned into pEGFP-N1 (Clontech) to obtain Vpr-EGFP. The vpr open reading frame of HIV-1 NL4-3 was also amplified with the oligonucleotide primer pair 5Ј-AA CTC GAG TGG AAC AAG CCC CAG AAG and 5Ј-GG AAG CTT CTA GGA TCT ACT GGC TCC ATT T to form a 306-bp product incorporating the XhoI and HindIII restriction sites. This fragment was cloned into the pEGFP-C1 (Clontech) vector to express EGFP-Vpr. For the construction of His-Vpr, vpr was amplified using the primer pair 5Ј-GGG AAG CTT GCC ACC ATG CAT CAT CAC CAT CAC CAT ATG GAA CAA GCC CCA GAA GAC CAA GGG CC and 5Ј-G GGC CTC GAG CTA GGA TCT ACT GGC TCC to incorporate the HindIII and XhoI restriction sites. The digested 337-bp product was cloned into pcDNA3.1/Myc-His(ϩ) A (Invitrogen) to express His-Vpr. The integrity of all constructs was confirmed by DNA sequencing.
The EGFP coding sequence was cut out of the EGFP-Vpr and Vpr-EGFP vectors with Age1 and BsrG1 and the equivalent EYFP (Clontech) sequence inserted. Hence, the vpr sequence and polylinker were identical.
Cell culture and transfections
The cell lines 293T, 293, and HeLa were grown in Dulbecco's modified Eagle's medium (Gibco-BRL), supplemented with 10% (v/v) heat-inactivated FCS, penicillin (100 U/ml), streptomycin (100 mg/ml), and L-glutamine (0.2 mM). Cells were seeded onto coverslips in six-well plates or into T25 cell-culture flasks and grown until 60 -70% confluent for transfection.
For cells on coverslips, 2.5 g (10 g for flasks) of plasmid DNA was added to 7.8 l (31 l) of 2 M CaCl 2 and the volume was adjusted to 62.5 l (250 l) with 10 mM Tris-HCl (pH 7.6). The CaCl 2 -DNA mix was added to 62.5 l (250 l) of HBS (50 mM HEPES, 1.5 mM Na 2 HPO 4 , 280 mM NaCl, pH 7.13) before adding the entire mixture dropwise to the cell-culture medium. Cells were incubated at 37°C with 5% CO 2 . After 16 h, cells were washed twice with PBS and fresh medium was added before returning the cells to the incubator until harvested.
Immunoblotting
Cells harvested from flasks were resuspended in 100 l of lysis buffer (0.5% v/v Nonidet P-40, 0.5% w/v sodium deoxycholate, 50 mM NaCl, 25 mM Tris-HCl, 10 mM EDTA, 20 mM phenylmethylsulfonyl fluoride in isopropanol, 0.01% w/v sodium azide, pH 8) and stored at Ϫ20°C until SDS-PAGE was performed using total cell lysates.
Total protein concentrations were calculated by a Bradford's assay (Bio-Rad) and equal amounts of total protein in 5ϫ loading buffer (10% v/v SDS; 500 mM dTT; 300 mM Tris, pH 6.8; 0.05% bromphenol blue) were electrophoresed on 12% SDS-PAGE gels (unless otherwise stated). The separated proteins were transferred to a Hybond-C Extra nitrocellulose membrane (Amersham) for analysis by immunoblotting. Membranes were blocked for 2 h in 5% w/v skim milk powder in TBS (0.4 M NaCl, 2.7 mM KCl, 20 mM Tris, pH 8) prior to incubation with either anti-GFP (Clontech) or anti-Vpr (no. 3252, Contributed by Dr. Velpadi Ayyavoo to the AIDS Research and Reference Reagent Program). Detection was performed using the chemiluminescent ECL system (Amersham).
Confocal microscopy
Cells transfected on coverslips were harvested at 48 h posttransfection. Cells were rinsed once in PBS and mounted onto slides with mounting medium (Dako). Images were collected using a Bio-Rad confocal microscope with the ϫ60 objective. A Z-series consisting of 15 to 20 sections, each 0.2 to 0.5 m in thickness, were collected and a representative section from the cell was selected. To ensure the selected confocal micrographs were representative, 10 to 12 fields of view (for each construct and each cell line) were photographed and the percentage of cells exhibiting a particular localization pattern was determined. Images were processed using Confocal Assistant (Bio-Rad).
Immunofluorescence studies
293T, 293, and HeLa cells were transfected on coverslips. At 48 h posttransfection the cells were washed in PBS, fixed in 3.5% (w/v) paraformaldehyde/PBS (10 min, RT), washed with PBS, and permeabilized with methanol:acetone (1:1, Ϫ20°C, 10 min). After drying, the cells were blocked with 1% (w/v) BSA/PBS (10 min, RT) prior to the addition of the primary antibodies. Cells were incubated at 4°C overnight with rabbit anti-Vpr (1 in 200; no. 3252, ARRRP) or mouse anti-His (5 g/ml, Boehringer Mannheim, USA). Some cells were also incubated with rabbit Ig or mouse Ig diluted to equivalent concentrations as control antibodies. All antibodies were diluted in 0.5% (w/v) BSA/ PBS. The cells were washed three times with PBS (5 min each wash) and incubated for 45 min at RT in the dark with a 1 in 50 dilution of anti-rabbit FITC or anti-mouse FITC, as appropriate. The cells were washed three times with PBS (5 min/wash) prior to mounting on slides and analysis by confocal microscopy.
Propidium iodide staining and FACS analysis
Harvested cells were pelleted and washed once in PBS prior to fixing at 1 ϫ 10 6 per ml in PBS containing 0.5% (v/v) formaldehyde and 0.1% (v/v) sodium azide for 1 h at 4°C. Cells were then washed twice in ice-cold PBS and resuspended in 70% (v/v) ethanol in PBS and incubated overnight at 4°C to permeabilize the cells. Next, cells were washed once in PBS and resuspended at a concentration of 1 ϫ 10 6 per milliliter containing 5 g/ml RNase (Boehringer Mannheim) and 50 g/ml propidium iodide (Sigma). Finally, the cells were incubated for 30 min at 37°C and then stored at 4°C overnight, prior to analysis by FACS using a Facstar Plus (Becton-Dickinson).
CaspACE FITC-VAD-FMK staining
A fluoroisothiocyanate (FITC) conjugate of the cell-permeable caspase inhibitor VAD-FMK, CaspACE FITC-VAD-FMK (Promega Corp., USA), binds to activated caspase and thus acts as an in situ marker for apoptosis.
CaspACE FITC-VAD-FMK assay was carried out as recommended by the manufacturer. Briefly, 0.5 ϫ 10 6 transiently transfected cells were pelleted by centrifugation at 125 g for 5 min at 20°C, then resuspended in 0.1 mL of DMEM-10 containing 10 M CaspACE FITC-VAD-FMK, and incubated for 20 min at 37°C in the dark. The cells were washed three times in PBS and resuspended in 0.5 mL of 3.5% (w/v) paraformaldehyde/PBS and stored at 4°C overnight. Doubly stained cells were analyzed on a FACStar Plus flow cytometer and analyzed using Winlist software (Verify Software House).
As a positive control for apoptosis, Actinomycin D (2.5 and 5 g/mL) was added to the medium of EYFP-transfected cells for 18 h before the cells were harvested and assayed for caspase activity (Nishizawa et al., 2000) . Actinomycin D blocks RNA polymerase II dependent transcription by binding to guanine residues in DNA (Herrmann and Mancini, 2001) , thereby inhibiting RNA synthesis and inducing endonuclease activation, hence apoptosis (Martin et al., 1990) .
